medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2011, Número 2

Siguiente >>

Ann Hepatol 2011; 10 (2)


Hepatology Highlights

Nahdi NA, Lam MCW, Yoshida EM

Idioma: Ingles.
Referencias bibliográficas: 18
Paginas: 115-118
Archivo PDF: 40.28 Kb.


FRAGMENTO

No abstract.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Charlton M. Nonalcoholic Fatty Liver Disease: A Review of Current Understanding and Future Impact. JAMA 2004; 2: 1048-58.

  2. Adams LA, Angulo P, Lindor K. Nonalcoholic Fatty Liver Disease. CMAJ 2005; 172(7): 899-905.

  3. Browning J, Szczepaniak L, Dobbins R, et al. Prevalence of Hepatic steatosis in an urban population in the United States: the impact of ethnicity. Hepatology 2004; 40: 1387-95.

  4. Giday SA, Ashiny Z, Naab T, et al. Frequency of Nonalcoholic fatty liver and degree of hepatic steatosis in African-American Patients. J Natl Med Assoc 2006; 98: 1613-15.

  5. Caldwell SH, Harris D.M, Patrie JT, et al. Is NASH underdiagnosed among African American? Am J Gastroenterol 2002: 97(6): 1496-500.

  6. Johnson RJ, Couser WG. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990: 37: 663-76.

  7. Bhimma R, Coovadia HM. Hepatitis B virus-associated nephropathy. Am J Nephrol 2004: 24: 198-211.

  8. 8 Lai KN, Tam JS, Lin HJ, Lai FM. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B virus surface antigenaemia. Nephron 1990: 54: 12-7.

  9. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009: 113: 2386-93.

  10. Makar GA, Weiner MG, Kimmel SE, et al. Incidence and prevalence of abnormal liver associated enzymes in patients with atrial fibrillation in a routine clinical care population. Pharmacoepidemiol Drug Saf 2008: 17: 43-51.

  11. Olivera-Martinez AM, Gallegos-Orezco JF. Recurrent Viral Liver Disease (Hepatitis B and C) After Liver Transplantation. Archives of Medical Research 2007; 38: 691-701.

  12. Lucey MR, Graham DM, Martin P, et al. Recurrence of hepatitis B and delta hepatitis after orthotopic liver transplantation. Gut 1992; 33: 1390.

  13. Starzl TE, Demetris AJ, Van Thiel D. Liver transplantation. N Engl J Med 989; 321: 1092.

  14. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. NEJM 1993; 329: 1842-7.

  15. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-5.

  16. Seehofer D, Berg T. Prevention of Hepatitis B Recurrence after Liver Transplantation. Transplantation 2005; 80: S120- S124.

  17. Marzano A, Gaia S, Ghisetti V, et al. Viral load at the time of liver transplantation and risk of hepatitis B virus recurrence. Liver Transpl 2005; 11: 402-9.

  18. Katz LH, Paul M, Guy D.G, et al. Prevention of recurrent HBV infectionafter liver transplantation: Hepatitis B immunoglobulin, antiviral drugs or both? Transpl Infec Dise 2010; 12: 292-308.




2020     |     www.medigraphic.com